Evaluation of four clinical laboratory parameters for the diagnosis of myalgic encephalomyelitis.
De Meirleir, Kenny L, Mijatovic, Tatjana, Subramanian, Krishnamurthy et al. · Journal of translational medicine · 2018 · DOI
Quick Summary
Researchers tested four substances in the blood of 140 ME/CFS patients and 140 healthy people to see if they could help diagnose the disease. They found that three specific markers—sCD14, prostaglandin E2, and interleukin 8—were most useful for identifying ME/CFS. These findings suggest that a simple blood test might one day help doctors confirm ME/CFS diagnosis more quickly and objectively.
Why It Matters
ME/CFS currently lacks objective diagnostic biomarkers, requiring costly subjective clinical assessments that often delay diagnosis. This study identifies specific blood markers that could potentially streamline diagnosis and validate ME/CFS as a biological disease, improving patient outcomes and research standardization.
Observed Findings
Serum sCD14 levels were significantly elevated in ME patients (coefficient 0.002, p=3×10⁻⁷)
Prostaglandin E2 showed the strongest association with ME diagnosis (coefficient 0.249, p=1×10⁻⁵)
Interleukin-8 levels were significantly elevated in ME cases (coefficient 0.005, p=3×10⁻³)
Inter-marker correlations were modest (range −0.26 to 0.61), suggesting they capture different biological aspects
Inferred Conclusions
A three-marker model combining sCD14, PGE2, and IL-8 may provide objective support for ME/CFS diagnosis
The inflammatory and immune activation markers suggest activation of innate immune pathways in ME/CFS pathophysiology
Blood-based biomarkers could potentially replace or supplement subjective diagnostic criteria currently used
Remaining Questions
Do these biomarker levels correlate with symptom severity, disease duration, or functional capacity in ME/CFS patients?
Can this three-marker panel be validated in an independent cohort and tested prospectively in suspected cases?
Do these markers change in response to treatment or over the disease course, and could they serve as outcome measures?
What This Study Does Not Prove
This study does not prove that these three markers directly cause ME/CFS—they may simply be associated with the disease. The findings require external validation in independent patient populations before clinical implementation, and the study does not establish whether these markers change over time or correlate with disease severity and progression.